Xiaodong Luo

Xiaodong Luo

Auto-generated profile, based on publicly available information

Xiaodong Luo

Evidence Generation & Decision Sciences, TMU, R&D, Sanofi US

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 March 2017 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
XLXiaodong Luo
Xiaodong Luo
JQJunshan Qiu
Junshan Qiu
SBSteven Bai
Steven Bai
HTHong Tian
Hong Tian

27 July 2020 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
JJJin Jin
Jin Jin
MRMarie‐Karelle Riviere
Marie‐Karelle Riviere
XLXiaodong Luo
Xiaodong Luo
YDYingwen Dong
Yingwen Dong

7 July 2020 in Annals of Internal Medicine
Verified
Journal Article
Closed access
BHBo Huang
Bo Huang
LTLu Tian
Lu Tian
ZMZachary McCaw
Zachary McCaw
XLXiaodong Luo
Xiaodong Luo
ETEnayet Talukder
Enayet Talukder
LWLee-Jen Wei
Lee-Jen Wei
This article describes a method for estimating treatment effects, the probability-of-being-in-response curve, which can be used to visualize how rapidly patients respond to therapy and how long the... In comparative studies, treatment effect is often assessed using a binary outcome that indicates response to the therapy. Commonly used summary measures for response include the cumulative and curr...

31 May 2023 in Journal of the Peripheral Nervous System
Verified
Journal Article
Open access
LQLuis Querol
Luis Querol
RLRichard A. Lewis
Richard A. Lewis
HHHans-Peter Hartung
Hans-Peter Hartung
PDPieter A. Van Doorn
Pieter A. Van Doorn
EWErik Wallstroem
Erik Wallstroem
RHRichard A. C. Hughes
Richard A. C. Hughes
Background and Aims: Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune‐mediated disease of the peripheral nerves, with significant unmet treatment needs. Clinical trials in CIDP are challenging; thus, new trial designs are needed. We present design of an open‐label phase 2 study (NCT04658472) evaluating efficacy and safety of SAR445088, a monoclonal antibody targeting complement C1s, in CIDP.Methods: This phase 2, proof‐of‐concept, multicenter, open‐label trial will evaluate the efficacy, and safety of SAR445088 in 90 patients with CIDP across three groups: (1) currently treated with standard‐of‐care (SOC) therapies, including immunoglobulin or corticosteroids (SOC‐Treated); (2) refractory to SOC (SOC‐Refractory); and (3) naïve to SOC (SOC‐Naïve). Enrolled participants undergo a 24‐week treatment period (part A), followed by an optional treatment extension for up to an additional 52 weeks (part B).In part A, the primary endpoint for the SOC‐Treated group is the percentage of participants with a relapse after switching from SOC to SAR445088. The primary endpoint for the SOC‐Refractory and SOC‐Naïve groups is the percentage of participants with a response, compared to baseline. Secondary endpoints include safety, tolerability, immunogenicity, and efficacy of SAR445088 during 12‐week overlapping period (SOC‐Treated). Part B evaluates long‐term safety and durability of efficacy. Data analysis will be performed using Bayesian statistics (predefined efficacy thresholds) and historical data‐based placebo assumptions to support program decision‐making.Interpretation: This innovative trial design based on patient groups and Bayesian statistics provides an efficient paradigm to evaluate new treatment candidates across the CIDP spectrum and can help accelerate development of new therapies.

3 October 2018 in Statistics in Medicine
Verified
Journal Article
Closed access
PDF file
XLXiaodong Luo
Xiaodong Luo
XMXuezhou Mao
Xuezhou Mao
XCXun Chen
Xun Chen
JQJunshan Qiu
Junshan Qiu
SBSteven Bai
Steven Bai
HQHui Quan
Hui Quan

1 July 2018 in Contemporary Clinical Trials
Verified
Journal Article
Closed access
HQHui Quan
Hui Quan
LQLi Qi
Li Qi
XLXiaodong Luo
Xiaodong Luo
LDLoic Darchy
Loic Darchy